{"id":4479,"date":"2015-12-17T12:11:53","date_gmt":"2015-12-17T12:11:53","guid":{"rendered":"https:\/\/www.seedcapitalbizkaia.eus\/ganar-la-partida-al-cancer\/"},"modified":"2021-03-15T11:09:47","modified_gmt":"2021-03-15T09:09:47","slug":"ganar-la-partida-al-cancer","status":"publish","type":"post","link":"https:\/\/www.seedcapitalbizkaia.eus\/en\/ganar-la-partida-al-cancer\/","title":{"rendered":"Winning the battle against cancer"},"content":{"rendered":"<h2 style=\"text-align: left;\"><em><strong><a href=\"http:\/\/oncomatryx.com\/es\/inicio\/\">Oncomatryx Biopharma<\/a> has been working since 2010 on the preparation of drugs that fight tumour stroma so that the treatments reach the tumour fully and destroy it<\/strong><\/em><\/h2>\n<p style=\"text-align: left;\">Why are some tumours cured for the vast majority of patients while for others there are no effective treatments? It is an issue that we have all paid attention more or less consciously and to which scientists have devoted enormous efforts and resources. One of the main hypotheses, supported by numerous empirical evidences, is that the different parts (cell types) that make up tumours have a direct relationship with the degree of effectiveness of the treatment to cure a certain kind of cancer.<\/p>\n<p style=\"text-align: left;\">There are some tumours that grow protected by a barrier of cells that are not the tumour itself and that, in addition to promoting its expansion, hinder the treatments from reaching the tumour fully: this is the so-called tumour stroma. Taking this as a basis, in 2010 Oncomatryx Biopharma began its activity with the objective of attacking the tumour stroma, to allow the treatments to reach the tumour fully and kill it.<\/p>\n<h3 style=\"text-align: left;\"><strong>Tumour stroma<\/strong><\/h3>\n<p style=\"text-align: left;\">In order to destroy the tumour stroma, Oncomatryx has developed a series of compounds called antibody-drug-conjugates (ADC). This new generation of drugs are the result of the union of an antibody, which acts as a guide, just carrying the compound inside the cells of the stroma and a chemical molecule that is released once it is inside them and; and then, it eliminates them. The use of these elements specifically directed against a type of \u201ctarget cells\u201d minimizes side effects and toxicity to healthy cells, one of the great problems of current treatments.<\/p>\n<p style=\"text-align: left;\">After years of development and excellent results in \u201cin vitro\u201d and \u201cin vivo\u201d models, Oncomatryx is now in a position to start the validation phases of the same in human patients, an essential previous step to be able to make available to patients these new treatments regularly. To begin this clinical validation, and to take care of patients\u2019 safety, regulatory agencies require any new drug to carry out a series of trials under conditions defined by these same agencies: it is the so-called preclinical regulatory.<\/p>\n<h3 style=\"text-align: left;\"><strong>Preclinical phase<\/strong><\/h3>\n<p style=\"text-align: left;\">The pre-clinical regulatory phase involves an investment of several million euros. <em>\u201cOur forecast is an expense of 4.500.000 euros in R&amp;D that is added to the 8.000.000 euros invested till today\u201d<\/em>, they indicate from Oncomatryx. The company has solved its financing through the entry of capital via new investors. In this sense, the managers of the company consider that <em>\u201c<a href=\"https:\/\/www.seedcapitalbizkaia.eus\/en\/\">Seed Capital<\/a>&#8216;s contribution came in three years ago; their experience and rigor when choosing in which companies and projects to invest its resources, has been fundamental for our company, not only in the economic sense, but also as an endorsement to the viability of the project and reinforcement of the confidence of other potential investors\u201d<\/em>.<\/p>\n<p style=\"text-align: left;\"><em>\u201cWith the funds for the development of the preclinical phase and the first clinical phase guaranteed thanks to the investors who have entered the share capital of Oncomatryx Biopharma <\/em>\u2013 they point out \u2013<em> the steps we are taking are leading us to obtain the authorization from the regulatory agencies to start safety and efficacy tests in human patients in the next 18 months\u201d<\/em>. The release to the \u201cmarket\u201d will happen once the phase of clinical trials in humans is finished; this is highly variable, but a realistic estimation could be between 3 and 5 years after starting it.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Oncomatryx Biopharma has been working since 2010 on the preparation of drugs that fight tumour stroma so that the treatments reach the tumour fully and&#8230;<\/p>\n","protected":false},"author":1,"featured_media":2292,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14],"tags":[],"class_list":["post-4479","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-noticias-eu-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Financiaci\u00f3n farmacos | Oncomatryx Biopharma | Seed Capital Bizkaia<\/title>\n<meta name=\"description\" content=\"Financiaci\u00f3n farmacos | \u201cla aportaci\u00f3n de Seed Capital, entr\u00f3 hace tres a\u00f1os, su experiencia y rigor a la hora de elegir en qu\u00e9 compa\u00f1\u00edas...&quot;\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.seedcapitalbizkaia.eus\/en\/ganar-la-partida-al-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Financiaci\u00f3n farmacos | Oncomatryx Biopharma | Seed Capital Bizkaia\" \/>\n<meta property=\"og:description\" content=\"Financiaci\u00f3n farmacos | \u201cla aportaci\u00f3n de Seed Capital, entr\u00f3 hace tres a\u00f1os, su experiencia y rigor a la hora de elegir en qu\u00e9 compa\u00f1\u00edas...&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.seedcapitalbizkaia.eus\/en\/ganar-la-partida-al-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Seed Capital Bizkaia\" \/>\n<meta property=\"article:published_time\" content=\"2015-12-17T12:11:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-15T09:09:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.seedcapitalbizkaia.eus\/wp-content\/uploads\/2015\/12\/laboratorio-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"donostik.com\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"donostik.com\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/en\\\/ganar-la-partida-al-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/en\\\/ganar-la-partida-al-cancer\\\/\"},\"author\":{\"name\":\"donostik.com\",\"@id\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/#\\\/schema\\\/person\\\/ddb022041ce4c99790aa462ccfd487d4\"},\"headline\":\"Winning the battle against cancer\",\"datePublished\":\"2015-12-17T12:11:53+00:00\",\"dateModified\":\"2021-03-15T09:09:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/en\\\/ganar-la-partida-al-cancer\\\/\"},\"wordCount\":576,\"image\":{\"@id\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/en\\\/ganar-la-partida-al-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/wp-content\\\/uploads\\\/2015\\\/12\\\/laboratorio-scaled.jpg\",\"articleSection\":[\"Noticias\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/en\\\/ganar-la-partida-al-cancer\\\/\",\"url\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/en\\\/ganar-la-partida-al-cancer\\\/\",\"name\":\"Financiaci\u00f3n farmacos | Oncomatryx Biopharma | Seed Capital Bizkaia\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/en\\\/ganar-la-partida-al-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/en\\\/ganar-la-partida-al-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/wp-content\\\/uploads\\\/2015\\\/12\\\/laboratorio-scaled.jpg\",\"datePublished\":\"2015-12-17T12:11:53+00:00\",\"dateModified\":\"2021-03-15T09:09:47+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/#\\\/schema\\\/person\\\/ddb022041ce4c99790aa462ccfd487d4\"},\"description\":\"Financiaci\u00f3n farmacos | \u201cla aportaci\u00f3n de Seed Capital, entr\u00f3 hace tres a\u00f1os, su experiencia y rigor a la hora de elegir en qu\u00e9 compa\u00f1\u00edas...\\\"\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/en\\\/ganar-la-partida-al-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/en\\\/ganar-la-partida-al-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/en\\\/ganar-la-partida-al-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/wp-content\\\/uploads\\\/2015\\\/12\\\/laboratorio-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/wp-content\\\/uploads\\\/2015\\\/12\\\/laboratorio-scaled.jpg\",\"width\":2560,\"height\":1707,\"caption\":\"oncomatryx trabaja en la lucha contra los tumores\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/en\\\/ganar-la-partida-al-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Winning the battle against cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/#website\",\"url\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/\",\"name\":\"Seed Capital Bizkaia\",\"description\":\"Seed Capital Bizkaia\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/#\\\/schema\\\/person\\\/ddb022041ce4c99790aa462ccfd487d4\",\"name\":\"donostik.com\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/74ab23f94706a994cd407940c03aad1d070505898936f3d9c9eb1b94919ac449?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/74ab23f94706a994cd407940c03aad1d070505898936f3d9c9eb1b94919ac449?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/74ab23f94706a994cd407940c03aad1d070505898936f3d9c9eb1b94919ac449?s=96&d=mm&r=g\",\"caption\":\"donostik.com\"},\"sameAs\":[\"https:\\\/\\\/www.seedcapitalbizkaia.eus\"],\"url\":\"https:\\\/\\\/www.seedcapitalbizkaia.eus\\\/en\\\/author\\\/donostik.com\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Financiaci\u00f3n farmacos | Oncomatryx Biopharma | Seed Capital Bizkaia","description":"Financiaci\u00f3n farmacos | \u201cla aportaci\u00f3n de Seed Capital, entr\u00f3 hace tres a\u00f1os, su experiencia y rigor a la hora de elegir en qu\u00e9 compa\u00f1\u00edas...\"","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.seedcapitalbizkaia.eus\/en\/ganar-la-partida-al-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Financiaci\u00f3n farmacos | Oncomatryx Biopharma | Seed Capital Bizkaia","og_description":"Financiaci\u00f3n farmacos | \u201cla aportaci\u00f3n de Seed Capital, entr\u00f3 hace tres a\u00f1os, su experiencia y rigor a la hora de elegir en qu\u00e9 compa\u00f1\u00edas...\"","og_url":"https:\/\/www.seedcapitalbizkaia.eus\/en\/ganar-la-partida-al-cancer\/","og_site_name":"Seed Capital Bizkaia","article_published_time":"2015-12-17T12:11:53+00:00","article_modified_time":"2021-03-15T09:09:47+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/www.seedcapitalbizkaia.eus\/wp-content\/uploads\/2015\/12\/laboratorio-scaled.jpg","type":"image\/jpeg"}],"author":"donostik.com","twitter_card":"summary_large_image","twitter_misc":{"Written by":"donostik.com","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.seedcapitalbizkaia.eus\/en\/ganar-la-partida-al-cancer\/#article","isPartOf":{"@id":"https:\/\/www.seedcapitalbizkaia.eus\/en\/ganar-la-partida-al-cancer\/"},"author":{"name":"donostik.com","@id":"https:\/\/www.seedcapitalbizkaia.eus\/#\/schema\/person\/ddb022041ce4c99790aa462ccfd487d4"},"headline":"Winning the battle against cancer","datePublished":"2015-12-17T12:11:53+00:00","dateModified":"2021-03-15T09:09:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.seedcapitalbizkaia.eus\/en\/ganar-la-partida-al-cancer\/"},"wordCount":576,"image":{"@id":"https:\/\/www.seedcapitalbizkaia.eus\/en\/ganar-la-partida-al-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.seedcapitalbizkaia.eus\/wp-content\/uploads\/2015\/12\/laboratorio-scaled.jpg","articleSection":["Noticias"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.seedcapitalbizkaia.eus\/en\/ganar-la-partida-al-cancer\/","url":"https:\/\/www.seedcapitalbizkaia.eus\/en\/ganar-la-partida-al-cancer\/","name":"Financiaci\u00f3n farmacos | Oncomatryx Biopharma | Seed Capital Bizkaia","isPartOf":{"@id":"https:\/\/www.seedcapitalbizkaia.eus\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.seedcapitalbizkaia.eus\/en\/ganar-la-partida-al-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.seedcapitalbizkaia.eus\/en\/ganar-la-partida-al-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.seedcapitalbizkaia.eus\/wp-content\/uploads\/2015\/12\/laboratorio-scaled.jpg","datePublished":"2015-12-17T12:11:53+00:00","dateModified":"2021-03-15T09:09:47+00:00","author":{"@id":"https:\/\/www.seedcapitalbizkaia.eus\/#\/schema\/person\/ddb022041ce4c99790aa462ccfd487d4"},"description":"Financiaci\u00f3n farmacos | \u201cla aportaci\u00f3n de Seed Capital, entr\u00f3 hace tres a\u00f1os, su experiencia y rigor a la hora de elegir en qu\u00e9 compa\u00f1\u00edas...\"","breadcrumb":{"@id":"https:\/\/www.seedcapitalbizkaia.eus\/en\/ganar-la-partida-al-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.seedcapitalbizkaia.eus\/en\/ganar-la-partida-al-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.seedcapitalbizkaia.eus\/en\/ganar-la-partida-al-cancer\/#primaryimage","url":"https:\/\/www.seedcapitalbizkaia.eus\/wp-content\/uploads\/2015\/12\/laboratorio-scaled.jpg","contentUrl":"https:\/\/www.seedcapitalbizkaia.eus\/wp-content\/uploads\/2015\/12\/laboratorio-scaled.jpg","width":2560,"height":1707,"caption":"oncomatryx trabaja en la lucha contra los tumores"},{"@type":"BreadcrumbList","@id":"https:\/\/www.seedcapitalbizkaia.eus\/en\/ganar-la-partida-al-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/www.seedcapitalbizkaia.eus\/en\/"},{"@type":"ListItem","position":2,"name":"Winning the battle against cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.seedcapitalbizkaia.eus\/#website","url":"https:\/\/www.seedcapitalbizkaia.eus\/","name":"Seed Capital Bizkaia","description":"Seed Capital Bizkaia","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.seedcapitalbizkaia.eus\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.seedcapitalbizkaia.eus\/#\/schema\/person\/ddb022041ce4c99790aa462ccfd487d4","name":"donostik.com","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/74ab23f94706a994cd407940c03aad1d070505898936f3d9c9eb1b94919ac449?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/74ab23f94706a994cd407940c03aad1d070505898936f3d9c9eb1b94919ac449?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/74ab23f94706a994cd407940c03aad1d070505898936f3d9c9eb1b94919ac449?s=96&d=mm&r=g","caption":"donostik.com"},"sameAs":["https:\/\/www.seedcapitalbizkaia.eus"],"url":"https:\/\/www.seedcapitalbizkaia.eus\/en\/author\/donostik.com"}]}},"_links":{"self":[{"href":"https:\/\/www.seedcapitalbizkaia.eus\/en\/wp-json\/wp\/v2\/posts\/4479","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.seedcapitalbizkaia.eus\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.seedcapitalbizkaia.eus\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.seedcapitalbizkaia.eus\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.seedcapitalbizkaia.eus\/en\/wp-json\/wp\/v2\/comments?post=4479"}],"version-history":[{"count":4,"href":"https:\/\/www.seedcapitalbizkaia.eus\/en\/wp-json\/wp\/v2\/posts\/4479\/revisions"}],"predecessor-version":[{"id":5305,"href":"https:\/\/www.seedcapitalbizkaia.eus\/en\/wp-json\/wp\/v2\/posts\/4479\/revisions\/5305"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.seedcapitalbizkaia.eus\/en\/wp-json\/wp\/v2\/media\/2292"}],"wp:attachment":[{"href":"https:\/\/www.seedcapitalbizkaia.eus\/en\/wp-json\/wp\/v2\/media?parent=4479"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.seedcapitalbizkaia.eus\/en\/wp-json\/wp\/v2\/categories?post=4479"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.seedcapitalbizkaia.eus\/en\/wp-json\/wp\/v2\/tags?post=4479"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}